Progenics Pharmaceuticals Inc
PGNX
PGNX was delisted on the 19th of June, 2020.
78 hedge funds and large institutions have $293M invested in Progenics Pharmaceuticals Inc in 2014 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 21 increasing their positions, 26 reducing their positions, and 13 closing their positions.
34% more capital invested
Capital invested by funds: $219M → $293M (+$73.6M)
20% more call options, than puts
Call options by funds: $1.33M | Put options by funds: $1.11M
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
3% more funds holding
Funds holding: 76 → 78 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
19% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$11.5M |
| 2 |
TM
Tiger Management
New York
|
+$6.43M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.82M |
| 4 |
RA
Royce & Associates
New York
|
+$3.39M |
| 5 |
FM
Forward Management
San Francisco,
California
|
+$2.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.57M |
| 2 |
Millennium Management
New York
|
-$570K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$388K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$381K |
| 5 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$376K |
PGNX Hedge Fund Activity: Q3 2014 in Review
78 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q3 2014, worth a combined $293M — up 34% from $219M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new PGNX positions and 13 closed out — a net gain of 2 holders — while 21 added to existing stakes and 26 trimmed.
The largest buyer was Broadfin Capital, adding an estimated $11.5M. The largest seller was Sabby Management, exiting entirely with an estimated $1.57M sold.
- 78 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q3 2014, up from 76 in Q2 2014.
- Funds reported $293M of Progenics Pharmaceuticals Inc stock for Q3 2014, up 34% quarter-over-quarter.
- 15 funds opened new Progenics Pharmaceuticals Inc positions in Q3 2014 and 13 closed out, a net change of +2 holders.
- The largest Progenics Pharmaceuticals Inc buyer in Q3 2014 was Broadfin Capital, an estimated $11.5M added.
- The largest Progenics Pharmaceuticals Inc seller in Q3 2014 was Sabby Management, an estimated $1.57M sold.
Based on aggregated 13F filings for Q3 2014.